Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRINOX + panitumumab
- Development stage
- Phase 2
- Lead developer
- Unicancer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FOLFIRINOX + panitumumab is an intensive combination therapy regimen consisting of the four-drug chemotherapy backbone FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) and the EGFR-targeting monoclonal antibody panitumumab. This regimen was specifically evaluated by the French oncology group UNICANCER in the Phase II PANIRINOX (UCGI28) trial for patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer (mCRC). The treatment strategy utilizes the synergistic effects of multi-agent cytotoxic chemotherapy and targeted EGFR inhibition to maximize tumor shrinkage and potentially convert unresectable metastases to resectable ones. Although the regimen demonstrated high overall response rates, results presented in 2025 indicated that it failed to meet its primary endpoint of complete response in patients with liver-limited disease compared to the standard mFOLFOX6 plus panitumumab regimen.
- Brand names
- EloxatinCamptosar
- Other names
- FOLFIRINOX-panitumumabFOLFIRINOX plus panitumumab
02
Targets
Beyond the preview
Go deeper on FOLFIRINOX + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRINOX + panitumumab.